Reported about 2 months ago
Morgan Stanley analysts have identified two stocks, COMPASS Pathways and Rocket Pharmaceuticals, with significant upside potential, suggesting gains up to 220% in the case of COMPASS. Both stocks are currently rated as Strong Buys, driven by positive clinical trial results and strong market opportunities in the biotech sector.
Source: YAHOO